drugset / Trial / NCT00254540
Study of SU011248 in Patients With Advanced Kidney Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
Timeline
- Start
- 2005-12
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 50 mg | Oral |